250+ investors that invest in your industry and stage
Get 250+ investors tailored to your startup
  • Invest in your industry and stage
  • Emails & contact info included
  • Excel and CSV export
  • Automatically
Trusted by 3,000+ startups

Top 50 Biotechnology Startup Investors in United States

A list of 50 angel investors and VC funds that invest in Biotechnology startups based in United states. We rank investors based on the number of investments they made in Biotechnology companies from United states. We update this investor list every month.

Top 50 Biotechnology Startup Investors in United States

Investor Biotechnology United States investments
ARCH Venture Partners 108
Alexandria Venture Investments 79
OrbiMed 70
New Enterprise Associates 70
Atlas Venture 63
Innova Memphis 63
Versant Ventures 63
5AM Ventures 62
MPM Capital 60
Polaris Partners 59
Third Rock Ventures 58
Khosla Ventures 55
F-Prime Capital 54
RA Capital Management 50
Canaan Partners 49
BioAdvance 49
Novartis Venture Fund 42
Lux Capital 41
Connecticut Innovations 40
Andreessen Horowitz 40
The Column Group 40
Google Ventures 39
KdT Ventures 39
Hatteras Venture Partners 39
Frazier Healthcare Partners 39
Fifty Years 38
DCVC 38
Sofinnova Investments 37
Northpond Ventures 35
Boston Harbor Angels 35
Dolby Family Ventures 35
Amgen Ventures 34
Pfizer Venture Investments 34
Alumni Ventures 33
Life Science Angels 33
Domain Associates 32
Refactor 31
Takeda Ventures 31
Wisconsin Investment Partners 30
North Carolina Biotechnology Center 30
Vivo Capital 30
Bay City Capital 29
Alta Partners 29
Casdin Capital 29
Novo Holdings 29
Rev1 Ventures 28
HealthCare Ventures 28
Founders Fund 28
SR One 28
iSelect Fund 27
Find investors that fund startups like yours. Automatically.
Our algorithm will find investors that invest in your industry, stage, and geography.
Investor list
ARCH Venture Partners VC Fund · Chicago, Illinois, United States · 19 investments in the past 12 months
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, China, United Kingdom
Portfolio highlights
  • Vilya — Vilya is a biotechnology company developing a novel class of drugs that precisely target the biology of disease. The company aims to create new medicines to leverage computing to make high throughput screening obsolete and cure diseases.
  • Metsera — Metsera operates as a clinical-stage biopharmaceutical company.
  • Xaira Therapeutics — Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research tobetter understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.
Alexandria Venture Investments VC Fund · Pasadena, California, United States · 13 investments in the past 12 months
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, France, Canada
Portfolio highlights
  • Umaro Foods — Umaro Foods specializes in developing a plant-based protein source from ocean-farmed seaweed.
  • Tome Biosciences — Tome Biosciences is a biotechnology company that develops programmable gene insertion technology. Using CRISPR, its technologies allow them to insert any genetic sequence of any size at any location into any genome.
  • Remix Therapeutics — Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.
OrbiMed VC Fund · New York, New York, United States · 46 investments in the past 12 months
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series A, Series C
  • United States, China, Israel
Portfolio highlights
  • TriSalus Life Sciences — Surefire Medical, based in Westminster, Colorado, was founded in 2009 to develop a novel infusion system for the interventional radiology market. The Surefire's Infusion System is designed to precisely deliver embolic agents through the sophisticated expandable tip portion of its catheter. Because of this differentiated expandable tip, whichcollapses in forwarding flow to maintain blood flow and dynamically expands to the vessel wall in reverse flow to minimize reflux, Surefire's Infusion System is designed to substantially reduce damage to healthy tissue.
  • Corvus Pharmaceuticals — Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
  • Sparrow Pharmaceuticals — Sparrow Pharmaceuticals is an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess.
New Enterprise Associates VC Fund · Menlo Park, California, United States · 44 investments in the past 12 months
Foundational partners to ambitious founders at every stage of company-building.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series B, Series A, Series C
  • United States, India, China
Portfolio highlights
  • Faircado — Stop wasting time and money - faircado helps you find the best pre-owned deals for your wallet and the planet.
  • Twelve Labs — Twelve Labs helps developers make programs that can see, listen, and understand the world as we do by giving them the most powerful video search API
  • Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology
Atlas Venture VC Fund · Cambridge, Massachusetts, United States · 11 investments in the past 12 months
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Korro Bio — Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in proteinstructure and function across multiple tissues.In 2018,
  • Pheon Therapeutics — Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England.
  • Diagonal Therapeutics — Diagonal Therapeutics pioneers a new era in medicine by advancing agonist antibody therapeutics targeting the root causes of devastating diseases. Discover our ground-breaking approach to reactivate critical biological pathways for transformative patient outcomes.
Innova Memphis VC Fund · Memphis, Tennessee, United States · 2 investments in the past 12 months
Founded in 2007 by the Memphis Bioworks Foundation, Innova is a pre-seed, seed and early-stage investor focused on starting and funding high-growth companies in the Biosciences, Technology and AgBio fields across the state of Tennessee. Innova links capital with great ideas to create groundbreaking products and services.At Innova we invest instart-up companies, help them grow, and then assist them in linking with established corporations for licensing, buy-outs or further investments. We provide the synergy of experienced management, market expertise and venture capital to accelerate the development of new products and services into viable business units that can stand on their own and then take their place with a mature market leader, if desired.Whether an innovation is still on the drawing board or stalled in the market place the Innova staff has the expertise, skills, and experience to envision and create a functioning business unit that is prepared to thrive in the market place. Technical know-how, market-proven staffing, and "just-right" funding assure the greatest chance possible for success.
Show more
Investment focus
  • Health Care, Medical, Medical Device
  • Seed, Pre-Seed, Convertible Note
  • United States, Argentina, United Kingdom
Portfolio highlights
  • Rantizo — Fly more acres, deliver better service. The equipment, tools, and expertise you need to be the grower's first call for drone spray services.
  • iYOTAH Solutions — iYOTAH Solutions is a transformational SaaS technology company that connects data to help the animal protein industry thrive.
  • Glanris — Glanris developed a completely green, non-toxic, filtration media for water purification from an agriculture by-product. This agricultural product is grown around the world, is plentiful, and can be used locally to ensure clean drinking water in developing countries. It also gives local farmers a significant additional income source for a productthat today they are throwing away.This media has been independently tested over the last two years of development and is ready for production.
Versant Ventures VC Fund · Menlo Park, California, United States · 7 investments in the past 12 months
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • United States, Switzerland, Canada
Portfolio highlights
  • Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
  • SixPeaks Bio — SixPeaks is developing a pipeline of medicines for healthy weight loss.
  • Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
5AM Ventures VC Fund · Menlo Park, California, United States · 7 investments in the past 12 months
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Silence Therapeutics — Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetictoolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types.
  • Latigo Biotherapeutics — Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability.
  • Adverum Biotechnologies — At Adverum, we are driven to establish ocular gene therapy as a new standard of care for debilitating retinal diseases.
MPM Capital VC Fund · Cambridge, Massachusetts, United States · 7 investments in the past 12 months
Powering Breakthroughs in Life Sciences
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series A, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • AstronauTx — AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.
  • Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
  • Frontier Medicines — Frontier Medicines is boldly advancing science to defeat disease by pioneering innovations in precision-based medicines to target undruggable therapies
Polaris Partners VC Fund · Boston, Massachusetts, United States · 20 investments in the past 12 months
Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.
Show more
Investment focus
  • Health Care, Biotechnology, Medical
  • Series B, Series A, Series C
  • United States, Ireland, Singapore
Portfolio highlights
  • Lore — Lore Health is a startup that combines artificial intelligence (AI) technology with social media to build a welcoming, encouraging, and judgment-free community where individuals may meet others who share their interests.
  • ByHeart — ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York.
  • Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
Third Rock Ventures VC Fund · Boston, Massachusetts, United States · 3 investments in the past 12 months
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States
Portfolio highlights
  • Rapport Therapeutics — Precision medicines to match the complexity of the human brain.
  • Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
  • Synnovation Therapeutics — Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers. It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small-molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.
Khosla Ventures VC Fund · Menlo Park, California, United States · 81 investments in the past 12 months
Khosla Ventures invests in companies that are bold, early and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs. Headquartered in Menlo Park, Calif., Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech,digital health, medtech and diagnostics, therapeutics and frontier technology.
Show more
Investment focus
  • Software, Health Care, Artificial Intelligence
  • Series A, Series B, Seed
  • United States, India, United Kingdom
Portfolio highlights
  • WindBorne Systems — WindBorne designs, builds, and operates a constellation of long-duration smart weather balloons targeting the most critical data in the atmosphere.
  • Honey Homes — Hassle-free Home Upkeep
  • Cartwheel — Cartwheel is a powerful text-to-animation platform. Type animate characters for video, game, app, ad, social, AR, or VR projects simply. It builds to help tell stories faster, and more creatively.
F-Prime Capital VC Fund · Cambridge, Massachusetts, United States · 33 investments in the past 12 months
F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more
Investment focus
  • Health Care, Biotechnology, Medical
  • Series A, Series B, Series C
  • United States, United Kingdom, China
Portfolio highlights
  • Ashby — Ashby is a developer of recruitment software used for high-growth companies. It develops usable, enterprise-grade employment software that enables company leaders, recruiters, and hiring managers to run their hiring process significantly better. It was founded in 2018 and is based in San Francisco, California.
  • Expressable — Expressable is an online speech therapy practice for everyone with a communication disorder. It has pioneered a parent-focused care model that uses technology and education to integrate speech therapy techniques into children's daily lives, improving outcomes and experiences.The company was founded in 2019 and is headquartered in Austin,Texas.
  • Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology
RA Capital Management VC Fund · Boston, Massachusetts, United States · 68 investments in the past 12 months
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series C, Series A
  • United States, United Kingdom, China
Portfolio highlights
  • Gameto — Gameto is a new breed of biotechnology company in female reproductive longevity
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • Bicycle Therapeutics — Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Canaan Partners VC Fund · Menlo Park, California, United States · 19 investments in the past 12 months
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Show more
Investment focus
  • Software, Biotechnology, Health Care
  • Series A, Series B, Series C
  • United States, United Kingdom, Israel
Portfolio highlights
  • Truveris — Truveris is a leading digital health company focused on delivering truth and clarity in pharmacy.
  • Reibus — Reibus is the leading platform for buying and selling steel and other metals, with end-to-end services including logistics and financing.
  • Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.
BioAdvance VC Fund · Philadelphia, Pennsylvania, United States
BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Funding Round, Series A
  • United States, Canada
Portfolio highlights
  • Senzo — SENZO HEALTH HAS DEVELOPED A REVOLUTIONARY LATERAL FLOW TEST WHICH DELIVERS THE SAME ACCURACY AS LABORATORY-BASED PCR, WITH RESULTS AVAILABLE WITHIN 10 MINUTES, AT A FRACTION OF THE COST.
  • KayoThera — KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.
  • Palvella Therapeutics — Palvella Therapeutics is committed to developing safe and effective therapies that specifically target the root cause of genetic skin diseases.
Novartis Venture Fund VC Fund · Basel, Basel-Stadt, Switzerland · 4 investments in the past 12 months
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
  • Hepalink — Hepalink is a manufactures ultra-pure pipeline control systems based on semiconductors and pan-semiconductor liquid circuits.
  • Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Lux Capital VC Fund · New York, New York, United States · 42 investments in the past 12 months
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series A, Seed, Series B
  • United States, Canada, United Kingdom
Portfolio highlights
  • LabGenius — Finding the next generation of drugs with machine learning, synthetic biology and laboratory automation
  • Maven AGI — Maven AGI is a technology company that focuses on the development of modern artificial intelligence (AI) solutions. Their primary aim is to reimagine the customer support experience by leveraging AI to lower costs, improve speed and quality, and drive efficiency. Their AI solutions are designed to unlock human potential by enabling teams to be moreproductive and giving them time back to do the work only humans can do. They also offer a range of services including customer acquisition strategy and operational planning. The company has a team size of 50 employees, with roles ranging from product management to sales and marketing.
  • Layup Parts — Layup is reshaping the composites industry by utilizing technology to manufacture high quality composite parts faster and more affordable than anyone else.
Connecticut Innovations VC Fund · Rocky Hill, Connecticut, United States · 13 investments in the past 12 months
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more
Investment focus
  • Health Care, Biotechnology, Software
  • Seed, Series A, Funding Round
  • United States, Israel, Canada
Portfolio highlights
  • Conduce Health — Conduce Health is a multi-specialty value-based care marketplace providing turnkey solutions for primary care organizations.
  • DeepLook Medical — Enhancing Medical Imaging with Revolutionary Software: DeepLook Medical envisions a future where data-driven imaging enables accurate, efficient, and personalized care across the entire treatment pathway.
  • Manifest Technologies — Manifest Technologies advances AI-powered computational neuroimaging system that quantifies neural and symptom data.
Andreessen Horowitz VC Fund · Menlo Park, California, United States · 111 investments in the past 12 months
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more
Investment focus
  • Software, Information Technology, Internet
  • Series A, Seed, Series B
  • United States, United Kingdom, Canada
Portfolio highlights
  • xAI — XAI is an AI company that develops a platform to accelerate human scientific discovery. The company primarily focuses on developing advanced AI systems that are truthful, competent, and maximally beneficial for all of humanity. Its mission is to understand the true nature of the universe.
  • ZeroMark — ZeroMark is a defense product company building technology to ensure safety and precision when using kinetic and non lethal weapons.
  • Valar Labs — AI to Make Oncologists Smarter
The Column Group VC Fund · San Francisco, California, United States · 7 investments in the past 12 months
The Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States
Portfolio highlights
  • Kenai Therapeutics — Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders. The company provides off-the-shelf neuron replacement medicines as effective disease-modifying treatments for neurological disorders, providing doctors with techniques to treat diseases like Parkinson's.
  • Accent Therapeutics — Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth anddifferentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, they aim to translate extraordinary science into life-changing therapies for patients.
  • Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
Google Ventures VC Fund · Mountain View, California, United States · 57 investments in the past 12 months
GV supports innovative founders moving the world forward.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series A, Series B, Seed
  • United States, United Kingdom, Canada
Portfolio highlights
  • Vercel — Vercel's Frontend Cloud gives developers the frameworks, workflows, and infrastructure to build a faster, more personalized web.
  • Verse — Define & achieve your financial and emissions reduction goals with Aria, a software platform that helps companies buy and manage clean power.
  • WitnessAI — WitnessAI - Enable safe, effective AI
KdT Ventures VC Fund · Austin, Texas, United States · 6 investments in the past 12 months
KdT Ventures is the standard for early-stage frontier science investing.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United States, Israel, Germany
Portfolio highlights
  • Elegen — Elegen is powering the bioeconomy with high-accuracy DNA synthesis that delivers industry-leading speed, length, and quality.
  • Motif Neurotech — Motif Neurotech is a company that develops minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses.
  • Radar Therapeutics — Precision-targeted, smart therapies to conquer the world's most intractable diseases.
Hatteras Venture Partners VC Fund · Durham, North Carolina, United States
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Funding Round
  • United States, Canada
Portfolio highlights
  • 410 Medical — 410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina.
  • Myeloid Therapeutics — Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyteapproach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.
  • Veralox Therapeutics — Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
Frazier Healthcare Partners VC Fund · Seattle, Washington, United States
With its purpose-driven culture and deep industry expertise, Frazier Healthcare is the preferred partner to profitable healthcare companies.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Post-IPO Equity
  • United States, Canada, Ireland
Portfolio highlights
  • Metagenomi — Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems.
  • Pardes Biosciences — Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines.The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.
  • New Amsterdam Pharma — NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
Fifty Years VC Fund · San Francisco, California, United States · 8 investments in the past 12 months
WE BACK HEROES using technology to solve the world's biggest problems
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United States, Germany, Canada
Portfolio highlights
  • Nabla Bio — Nabla is an autoreverse platform that enables the rapid discovery of previously unattainable protein variants with supernatural qualities. Nabla Bio makes new medicines and improve nutrition by engineering novel proteins.
  • The Bot Company — The Bot Company a household robot startup.
  • Cosmic Aerospace — Cosmic Aerospace is a pioneering aerospace technology company dedicated to advancing the boundaries of propulsion systems and enabling innovative solutions for space exploration. The company collaborates with leading space agencies, research institutions, and commercial partners to design, test, and implement these groundbreaking technologies.
DCVC VC Fund · San Francisco, California, United States · 13 investments in the past 12 months
We are deep tech venture capital.
Show more
Investment focus
  • Software, Artificial Intelligence, Health Care
  • Seed, Series A, Series B
  • United States, Canada, United Kingdom
Portfolio highlights
  • Fervo Energy — Fervo Energy delivers 24/7 carbon-free energy through development of next-generation geothermal projects.
  • Kairos Aerospace — Kairos Aerospace provides large-scale, aerial monitoring of methane emissions. The company completed the first-ever basin-wide aerial survey for methane detection in its 2019 survey of the Permian Basin. Kairos Aerospace’s mission is to improve operational excellence for the oil and gas industry with cost-effective, efficient methane reductions atscale.
  • Relation Therapeutics — Relation uses machine learning to develop drugs for pressing unmet need.
Sofinnova Investments VC Fund · Menlo Park, California, United States · 6 investments in the past 12 months
Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series A, Series C
  • United States, France, Switzerland
Portfolio highlights
  • Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.
  • Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
  • Aeovian Pharmaceuticals — Aeovian is a San Francisco based biopharmaceutical company developing novel and highly selective therapeutics modulating mTORC1 pathway.
Northpond Ventures VC Fund · Bethesda, Maryland, United States · 8 investments in the past 12 months
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more
Investment focus
  • Biotechnology, Health Care, Life Science
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Totus Medicines — Applying revolutionary chemical biology technologies to create life-changing covalent therapeutics for untreatable diseases.
  • SeLux Diagnostics — SeLux Diagnostics is a developer of the Next-Generation Phenotyping (NGP) platform that enables personalized antibiotic therapies for patients. The company was founded in 2014 and is based in Charlestown, MA.
  • Elephas — Elephas is a live tumor imaging company developing novel cancer diagnostic solutions to predict treatment outcomes and accelerate drug development.
Boston Harbor Angels VC Fund · Boston, Massachusetts, United States
Boston Harbor Angels is a group of proven business leaders interested in investing a portion of their assets in high growth, early stage companies. The group was formed in February 2004 and since then has made a number of investments in companies in medical devices, IT, consumer products, business products, specialty materials, Internet, aviation,etc. They believe they contribute more than money to the companies they fund and welcome the opportunity to work with entrepreneurs open to take advice, yet having the smarts and determination to make the company successful.Their focus is on early stage companies usually looking to raise $250K to $1.5M, where they can fund a portion of the round and syndicate the deal with other angel groups or early stage venture funds. The stage of the company should be close to commercialization, while the company should have a clear and defensible competitive advantage. They are looking for capital efficient businesses, which can reach profitability with less than $5M of equity investment and provide at least 10X return on the investment within 5 years.They do not invest as a fund - each of their members makes his or her individual investment decision but they collaborate in Due Diligence. They have a deep expertise in the life sciences field where they usually take the position of a lead investor, but are open to any opportunities that can make a strong business case. In some cases they prefer to be the follow on investor if they cannot identify a person with strong expertise within their group.The group’s strategy is directed by an executive committee which consists of 8 people elected by the group: Wayne Griffith (chairman), Bill McPhee, Henry Kay, Jay Schwartz (membership director), Steve Andress, Peter Miller, Don Freeman and Mic Williams (president and founder). The group’s day-to-day operations are managed by Boris Batchvarov (managing director).They receive 20-30 business summaries each month, out of which they select 8 companies to make a personal presentation to their screening committee. The screening committee consists of volunteers from the group. The presentations are 10 min long followed by 10 min Q&A. 4 of the companies are invited to present to the whole group, with the idea to get the people interested and decide to perform a Due Diligence with the companies before making an investment.
Show more
Investment focus
  • Biotechnology, Health Care, Medical Device
  • Angel, Seed, Series A
  • United States, Canada, India
Portfolio highlights
  • Zylö Therapeutics — Patented technology that enables, for topicals, sustained release, increased druggability, a Patchless Patch concept, and enhanced targeting of pores and follicles
  • Xeno Biosciences — Xeno Biosciences operates as a biopharmaceutical company pioneering a novel class of therapeutics to address large unmet needs in metabolic diseases. Lead program, XEN-101, is a first-in-class, oral formulation designed to shift the gut microbiome to the weight-loss associated state induced by Roux-en-Y Gastric Bypass (RYGB) surgery.It wasfounded in 2015 and is headquartered in Somerville, Massachusetts.
  • Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
Dolby Family Ventures VC Fund · San Francisco, California, United States · 7 investments in the past 12 months
Dolby Family Ventures is an early stage venture firm focused on building great technology companies. They partner with best-in-class innovators and strong investment syndicate partners at the seed stage of a company’s development. Unlike many seed investors, They intend to continue to invest across future rounds in our successful portfoliocompanies.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Seed, Series B
  • United States, Austria, Israel
Portfolio highlights
  • LeoLabs — LeoLabs' network of ground-based, phased array radars produces high-resolution data on objects in LEO, supporting satellite service industries.
  • Progentos Therapeutics — Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
  • Esper Satellite Imagery — Welcome to Esper Satellite Imagery. Enjoy your Stay.
Amgen Ventures VC Fund · San Francisco, California, United States
Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, andcardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, Canada, United Kingdom
Portfolio highlights
  • Inversago Pharma — Inversago Pharma is a preclinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
  • Casma Therapeutics — Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomalstorage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.
  • Feldan Therapeutics — Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle.
Pfizer Venture Investments VC Fund · New York, New York, United States · 8 investments in the past 12 months
Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, United Kingdom, Switzerland
Portfolio highlights
  • Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
  • MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
  • Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.
Alumni Ventures VC Fund · Manchester, New Hampshire, United States · 150 investments in the past 12 months
Alumni Ventures offers diversified venture portfolios to accredited investors into highly competitive deals that individuals typically do not have access to on their own.
Show more
Investment focus
  • Software, Information Technology, Health Care
  • Seed, Series A, Series B
  • United States, United Kingdom, Canada
Portfolio highlights
  • CaseMark — CaseMark revolutionizes legal processes with its AI-driven Workflow platform, streamlining routine tasks while upholding the highest standards of privacy and security. Powered by advanced models like GPT-3.5 and GPT-4 turbo, and hosted on the robust Azure infrastructure, it's the trusted choice for modern legal professionals. With CaseMark, efficiency meets excellence in every legal operation.
  • TransCrypts — We all have that file box where we throw all our important documents. Our goal at TransCrypts is to make that box digital and have all the documents secured through the blockchain. We currently offer industry leading privacy and security standards on our file storage and sharing platform and have solutions for individuals all the way to enterprises.
  • Frore Systems — Frore Systems is a operator of an engineering company intended to offer micro electromechanical systems.The company is currently operating in a Stealth mode.
Life Science Angels VC Fund · Sunnyvale, California, United States
Life Science Angels, Inc. (LSA) is the premier angel investment group focused solely on healthcare investing, including medical devices, diagnostics, pharmaceuticals, biotechnology, and digital health.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Funding Round, Seed, Series A
  • United States, Israel, The Netherlands
Portfolio highlights
  • InnoSIGN — We are passionate to bring to market our OncoSIGNal pathway activity profiling technology contributing to a better understanding of disease mechanisms in oncology. OncoSIGNal enables next generation precision medicine by translating molecular data into functional cell behavior.
  • Allyx Therapeutics — Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies designed to reverse neurodegeneration. Allyx Therapeutics' product is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to get a drug that is capable of delivering a disease-modifying approach and preservecognition in patients.
  • Avisi Technologies — Avisi Technologies is developing a nanotechnology-enabled defense against blindness from glaucoma.
Domain Associates VC Fund · San Diego, California, United States
INVESTMENT ADVISORS TO THE FIRST VC FUND DEDICATED TO BIOTECH INVESTMENT MANAGER OF 9 SUBSEQUENT BIOTECH VC FUNDS
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series C, Series A
  • United States, Canada, Estonia
Portfolio highlights
  • Epic Sciences — Epic Sciences develops clinical solutions that accelerate drug development and guided therapy across cancer drug indications. Epic's new AR-V7 CTC liquid biopsy test is the first clinically proven predictive test for metastatic castration-resistant prostate cancer.
  • Antios Therapeutics — This is an example page. It's different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I'm a bike messenger
  • Fractyl Health — Our vision is to develop transformative therapies that have the potential to prevent and eliminate metabolic diseases. We are a mission-driven team of innovators, singularly
Refactor VC Fund · Burlingame, California, United States
Refactor Capital is an early-stage venture capital firm that invests in founders solving fundamental human problems.
Show more
Investment focus
  • Health Care, Biotechnology, Medical
  • Seed, Series A, Series B
  • United States, United Kingdom, New Zealand
Portfolio highlights
  • Melonfrost — Melonfrost has created a novel way to optimize strains, eliminating the biggest bottleneck in the bioeconomy. By combining machine learning and evolution, our proprietary AI + Hardware platform steers the evolution of cells in real-time. Our algorithms explore the biological space and make decisions, while innovations in robotics, sensing, fluidicsand environmental control replace scientific labor, shaving years off the time to market for bioproducts. Evolution, from millenia to months.
  • Hyfé — Hyfé Foods is a biotech company producing ingredients by leveraging fungal fermentation to upcycle water byproducts from food manufacturers.
  • Macro Oceans — Transforming seaweed into low-carbon chemicals for materials, food, cosmetics and more
Takeda Ventures VC Fund · San Diego, California, United States
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Funding Round
  • United States, United Kingdom, Israel
Portfolio highlights
  • Cerevance — Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle theearly onset of various neurological diseases.
  • OncoResponse — OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.
  • Larkspur Biosciences — Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.
Wisconsin Investment Partners VC Fund · Madison, Wisconsin, United States · 2 investments in the past 12 months
Wisconsin Investment Partners is an Angel Investment Group in Madison, Wisconsin founded in 2000 with 20 members. Membership has grown to 50+ members in recent years, bringing significant knowledge and experience.
Show more
Investment focus
  • Health Care, Biotechnology, Medical
  • Funding Round, Seed, Series A
  • United States, Canada, United Kingdom
Portfolio highlights
  • Flyte — Flyte promotes cellular healing in pelvic floor muscles for lasting results. Flyte is fast, proven, safe, pelvic floor therapy for bladder control.
  • BeeReaders — ## Build Setup
  • Midwest Games — Midwest Games is a video game publisher focused on creating opportunities for the abundant talent across the Midwest and other underrepresented regions.
North Carolina Biotechnology Center VC Fund · Alexander, North Carolina, United States
The North Carolina Biotechnology Center is a private, non-profit corporation funded by the N.C. General Assembly to strengthen biotechnology research, business and education statewide. The Center is not a site for laboratory research; it works to support job creation in the biotechnology industry.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Debt Financing, Grant, Funding Round
  • United States, United Kingdom
Portfolio highlights
  • Avior Bio — Innovative Drug Delivery. Improved Therapeutics.
  • Phase — Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.
  • Amalgent Therapeutics — Repurposing Existing Drugs to Make Pain Relief Safer
Vivo Capital VC Fund · Palo Alto, California, United States · 12 investments in the past 12 months
Vivo Capital is a healthcare focused investment firm formed in 1996 that is currently making investments from its $1.4B Vivo Capital Fund IX into promising private healthcare companies and from its $635M Vivo Opportunity Fund into promising public healthcare companies.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series C, Series A
  • United States, China, United Kingdom
Portfolio highlights
  • Ajax Therapeutics — Ajax Therapeutics is an NYC-based biotechnology company applying computational chemistry and structure-based technologies to develop novel small molecules for hematologic malignancies
  • Silence Therapeutics — Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetictoolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types.
  • Adverum Biotechnologies — At Adverum, we are driven to establish ocular gene therapy as a new standard of care for debilitating retinal diseases.
Bay City Capital VC Fund · San Francisco, California, United States
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, they have managed six venture funds representing $1.5 billion in capital invested in over 70 companies. Five of these funds are general life sciences funds, and one is a nutrition andagribusiness sector fund.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series A, Series C
  • United States, Canada, Denmark
Portfolio highlights
  • Oculis — The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.
  • Bridge Medicines — MEET BRIDGE MEDICINES Bridge Medicines biotech company launched in partnership with Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management. Our mission is to move breakthrough research to the patient by bringing the
  • Sembiosys Genetics — SemBioSys Genetics Inc., a Canadian biotechnology company, announced today that it has signed a feasibility agreement with Dow AgroSciences LLC, of Indianapolis, Indiana, for the Stratosome(TM) Biologics System and its application to animal health biologics. Under the terms of the agreement, SemBioSys and Dow AgroSciences will engage incollaborative research with the aim of determining if the Stratosome(TM) Biologics System can enable the commercialisation of a Dow AgroSciences plant-made vaccine. Under the terms of the agreement, SemBioSys will receive upfront and milestone payments. Further terms of the agreement were not disclosed. "We believe that our Stratosome(TM) Biologics System, with its economic and functional benefits, makes it an outstanding platform for animal health products. We are extremely pleased to be working with Dow AgroSciences in developing their vaccine," said Andrew Baum, president and CEO of SemBioSys."We are very pleased to be working with SemBioSys in evaluating the Stratosome(TM) technology and its application to plant-made biologics for the animal health industry," stated Butch Mercer, Global Business Leader, Animal Health and Nutrition for Dow AgroSciencesThis is the third funded development agreement announced by SemBioSys in the last six months. In December, SemBioSys announced that it had executed a development agreement with Martek Biosciences Corporation (Nasdaq: MATK) to co- develop value-added specialty oil products (DHA containing safflower oil) with potential pharmaceutical and nutraceutical applications. In February, SemBioSys announced that it had entered into an agreement with Syngenta for access to SemBioSys' proprietary oilbody based Stratosome(TM) Biologics and StratoCapture(TM) Purification Systems for the development of Syngenta's biologic products.About SemBioSys Genetics Inc. (www.sembiosys.com)Calgary, Alberta-based SemBioSys Genetics Inc. is a privately held biotechnology company focused on the development of therapeutic proteins and oils using its proprietary oilbody-based technology - the Stratosome(TM) Biologics System. Spun out of the University of Calgary in 1994, the company's investors include Bay City Capital, Dow AgroSciences Canada, Inc., Ventures West Management Inc., BDC Venture Capital, University Technologies International Inc., RBC Capital Partners and Maurice Moloney Ph.D. scientific founder and chief scientific officer. In addition to these investors, SemBioSys has received repayable contributions of CAD$5.5MM from Technology Partnerships Canada, an agency of Industry Canada, and CAD$4.9MM from AVAC Ltd. SemBioSys has partnerships with Syngenta Participations AG and Martek Biosciences for the use of its Stratosome(TM) technology for the development of therapeutic products.
Alta Partners VC Fund · San Francisco, California, United States · 7 investments in the past 12 months
Alta Partners is a leading healthcare and life sciences venture capital firm, helping entrepreneurs build high-impact companies since 1996.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series A, Series C
  • United States, United Kingdom, China
Portfolio highlights
  • Transcarent — The One Place for Health and Care
  • Edgewood Oncology — Edgewood Oncology is a clinical-stage biotechnology business established to fulfill the potential of BTX-A51 for patients with solid tumors that are genetically specified and hematologic malignancies. Our goal is to create a novel treatment that will prolong and enhance the lives of those with the greatest unmet medical needs.
  • Progentos Therapeutics — Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
Casdin Capital VC Fund · New York, New York, United States · 4 investments in the past 12 months
Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, France, China
Portfolio highlights
  • ROME Therapeutics — ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier inbiology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.
  • Remix Therapeutics — Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.
  • BridgeBio Oncology Therapeutics — BridgeBio Oncology Therapeutics operates as a biopharmaceutical company.
Novo Holdings VC Fund · Hellerup, Hovedstaden, Denmark · 17 investments in the past 12 months
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series A, Series B, Series C
  • United States, Denmark, United Kingdom
Portfolio highlights
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • CIRCTEC — CIRCTEC is an innovator and operator of pyrolysis technology to recycle waste into renewable fuels and circular chemicals. It focus is on innovation and technology leadership, scaling sustainability in the chemical, petrochemical and oil sectors.
  • CARGO Therapeutics — CARGO Therapeutics develops CAR T-cell therapy to overcome cancer treatment resistance and address access barriers so that more patients can benefit from potentially curative therapies. The company is on a mission to outwit cancer by developing best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite commercially available autologousCARs advancements, these treatments are curative for less than half of all cancer patients. Furthermore, far too many patients are unable to access these potentially curative therapies due to other obstacles such as manufacturing, supply constraints, long turnaround times, and reimbursement barriers. CARGO's team is intensely focused on pursuing novel solutions to improve cancer treatment outcomes and experiences.
Rev1 Ventures VC Fund · Columbus, Ohio, United States · 10 investments in the past 12 months
Rev1 Ventures provides seed stage venture capital funding in Columbus, Ohio along with startup services, space, mentoring, and connections. Learn more!
Show more
Investment focus
  • Software, Health Care, Information Technology
  • Seed, Series A, Funding Round
  • United States, Germany
Portfolio highlights
  • Trace — Trace is the simplest way ever to create AR content and experiences for your product and business.
  • Champ — Through the application of its secure, patent-pending technology, CHAMPtitles ends the reliance on legacy systems to manage U.S. automobile titles. CHAMPtitles partners with each party in the vehicle title ecosystem to reduce their costs in handling titles, turning the burdensome administrative process of issuing a vehicle title into a profitableactivity.
  • Niobium Microsystems — Niobium Microsystems creates custom integrated circuit and microelectronic system solutions for clients with complex power, performance, and security constraints.
HealthCare Ventures VC Fund · Cambridge, Massachusetts, United States
HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, focused companies with potential to transform patient care.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series A, Series C
  • United States, Australia, United Kingdom
Portfolio highlights
  • Colorescience — Know Better Skin with Colorescience. From mineral sunscreen to clinical skincare products, achieve a clear, even complexion and protect your skin from the damaging effects of the sun and environmental aggressors such as pollution. Shop Now!
  • Leap Therapeutics — Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in acquiring and developing novel therapeutics. The company focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology.
  • Proteostasis Therapeutics — Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, aredesigned to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.
Founders Fund VC Fund · San Francisco, California, United States · 48 investments in the past 12 months
Founders Fund is a San Francisco based venture capital firm investing in companies building revolutionary technologies.
Show more
Investment focus
  • Software, Health Care, Internet
  • Series A, Seed, Series B
  • United States, United Kingdom, Germany
Portfolio highlights
  • Literati — Based in Austin,Texas Literati is a subscription book club company. Since 2017, Literati has provided a unique try-before-you-buy book club service to kids 12 and under. Most recently the company has expanded its product line, offering book clubs curated by “luminaries,” a collection of authors, intellectuals, and other notable figures.Literati's team is made up of product people, perfectionistic designers, philosophical hackers, and straight-up hustlers on a mission to build revolutionary excitement in literature. The company was founded in 2017 and is based in Austin, Texas.
  • inspeq ai — Inspeq AI uses metric-based evaluation and improves model performance, helps detect responses with low factual accuracy, and prevents them before serving to the end-users.
  • Polymarket — Bet on your beliefs
SR One VC Fund · Cambridge, Massachusetts, United States · 5 investments in the past 12 months
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Avalyn Pharma — This does NOT display on the home page
  • Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
  • Odyssey Therapeutics — Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases
iSelect Fund VC Fund · St Louis, Missouri, United States · 3 investments in the past 12 months
Venture investing in Food, Health, and AgTech. A generational investment thesis. Food is Health is longevity
Show more
Investment focus
  • Biotechnology, Health Care, Agriculture
  • Seed, Series A, Series B
  • United States, Australia
Portfolio highlights
  • MEND — Mend is the scientifically proven way to heal and enhance your body faster.
  • Triplebar — Triplebar provides sustainability, biotechnology, and synthetic biology research.
  • Pluton Biosciences — The miniscule organisms Pluton Biosciences discover possess the power to create global change. Pluton quickly and inexpensively taps into the diverse world of bacteria, fungi and viruses to discover next-generation products for carbon sequestration, agriculture, pharmaceutical, biomaterials and bioremediation.Pluton Bioscience's discoveryprocess generates diverse commercialization options, including: Organisms (biological products), Small Molecule Chemistries (fermentable and non-fermentable) and New Traits (scale dependent).
Investors by industry
Investors by country
Investors in United States by industry